Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
QED Therapeutics
Palo Alto, California, United Statesqedtx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
QED Therapeutics has developed infigratinib (BGJ398), an orally administered selective inhibitor of FGFR1–3. Infigratinib received FDA breakthrough therapy designation for achondroplasia and has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. The company’s current focus centers on rare skeletal dysplasias such as achondroplasia and hypochondroplasia. Recent clinical results include positive feedback from regulatory agencies regarding pivotal trials and promising Phase II data in pediatric achondroplasia patients.[1][6]
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Small molecules (notably FGFR kinase inhibitors)[4][5]
- Industry
- Biotech
02
Partnerships
Helsinn Group—strategic collaboration to co-develop/commercialize infigratinib outside the U.S. for oncology indications; BridgeBio retains rights to skeletal dysplasias.[2]
Beyond the preview
Go deeper on QED Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QED Therapeutics.